The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC
Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of the NIFTY study, a multicenter comparative randomized Phase IIb study evaluating liposomal irinotecan in combination with fluorouracil (5FU) and leucovorin in patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin. In this study, liposomal irinotecan + 5FU and leucovorin significantly improved progression-free survival and overall survival compared to 5FU/leucovorin in biliary tract cancer patients who progressed on prior gemcitabine plus cisplatin. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
